Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Mylan EPD to Take Over EpiPen from Pfizer in Japan
December 22, 2017
- Mitsubishi Tanabe Seeks to Call Off Cell Therapy Deal with South Korea’s KLS
December 21, 2017
- Pfizer, Maruishi File Precedex for Pediatric Use
December 21, 2017
- Otsuka Partners with US Biotech X-Chem on Oncology Drug Discovery
December 21, 2017
- GSK Japan Pres. Kikuchi to Quit after Only 9 Months in Office
December 20, 2017
- Fujifilm Grabs Stake in Genome Editing Startup, Makes Inroads into Gene Therapy Space
December 20, 2017
- JCR, Medipal to Form US Joint Venture Next Month
December 20, 2017
- Ono Cuts Computational Drug Discovery Deal with Schrödinger
December 20, 2017
- Gilead Aiming to Develop World’s First NASH Treatment, Hoping for Approval in 2020
December 20, 2017
- Pfizer to Lift Selara Shipment Adjustment, Normalizing Supply of All Hurricane-Hit Products
December 20, 2017
- Mundipharma to Enter Japanese Anesthesia Market with Remimazolam Licensed from German Company
December 20, 2017
- Janssen, Taiho to Copromote Psoriasis Med Guselkumab
December 19, 2017
- Kyowa Kirin’s Burosumab Gains European Panel Backing for Conditional Approval
December 19, 2017
- Pfizer, Takeda to End Xeljanz Distribution/Copromotion Scheme
December 19, 2017
- Takeda/TiGenix Cell Therapy for Crohn’s Disease Complication Gets European Panel Nod
December 19, 2017
- Authorized Generic Makers Thrive in April-September, but Pricing Overhaul Casts Cloud on Their Outlook
December 18, 2017
- Sawai Wins Supreme Court Victory in Elplat Patent Suit
December 18, 2017
- Pfizer’s Ibrance Now Available in Japan
December 18, 2017
- Ethical Drug Sales Up 6.4% in October on Keytruda/SGLT-2 Boost: Crecon
December 18, 2017
- 1st Sakigake-Designated Product Earns Approval
December 18, 2017
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…